Valeant's new chief cuts a familiar figure
Joseph Papa pursued a series of strategies at Perrigo that were similar to the drugmaker's discredited business model
New York
WHEN a deeply troubled company replaces its chief executive, it makes sense to expect the new CEO to bring a fresh take to its operations. A clean sweep, so to speak.
But if shareholders in Valeant Pharmaceuticals International envisage a vastly different approach by Joseph Papa, the company's incoming chief executive, they may be disappointed. That's because in the almost 10 years that Mr Papa headed Perrigo Co, a maker and distributor of over-the-counter and generic prescription drugs, the company pursued a series of strategies that were very Valeant-esque.
They include a merger with a foreign company that allowed Perrigo to slash i…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself